ER-phagy mediates the anti-tumoral synergism between HDAC inhibition and chemotherapy
Abstract Background Histone deacetylase inhibitors (HDACi) are clinically approved drugs for the treatment of hematological malignancies synergizing with chemotherapy. However, despite the long history of HDACi, the mechanistic underpinnings of this synergism have remained unclear. Methods Using tra...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
BMC
2025-04-01
|
| Sraith: | Cell Communication and Signaling |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1186/s12964-025-02198-9 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|